Type 2 diabetes

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Public, CGM, Diabetes, Patient, Glucose meter, Trinity, Physician, Bayer, Waveform, Acquisition, Letter, EST, Type 2 diabetes, Pharmaceutical industry

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.

Key Points: 
  • Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
  • In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
  • To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
  • Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Retrieved on: 
Wednesday, January 31, 2024
ROS, Inflammation, Uric acid, Insulin resistance, Research, Obesity, Cardiovascular disease, Glucose, Type, OGTT, Hypertension, ASC, Therapy, Journal of Translational Medicine, Risk, Journal, Type 2 diabetes, Serum, Translational medicine, NLRP3, Oxidative stress, Inflammasome, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • In the paper titled, “Altered insulin secretion dynamics relate to oxidative stress and inflammasome activation in children with obesity and insulin resistance,” the authors conducted a case-controlled study of 132 children who were either lean or obese.
  • The authors concluded, “It is insulin response to an OGTT that identifies children with obesity suffering oxidative stress, and inflammasome activation more specifically.
  • “The research published in the Journal of Translational Medicine points to a significant role for inflammasome-mediated inflammation and oxidative stress in development of metabolic complications in obese children.

Cardiometabolic Health Congress (CMHC) To Host DIETARY STRATEGIES FOR REVERSING TYPE 2 DIABETES: Advances, Perspectives, and Expert Discussions Live Webinar in Honor of the Late Dr. Sarah Hallberg

Retrieved on: 
Tuesday, January 30, 2024
CMHC, Annual, Insulin resistance, Research, TED, TED (conference), MD, Diet, Conditional sentence, Faculty, Type 2, Sugar, Insulin, Diabetes, Type 2 diabetes, Health

Boca Raton, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- On Saturday, February 24, at 9:00 AM EST , the Cardiometabolic Health Congress (CMHC)  will host a 4.5-hour live, complimentary legacy course in honor of the late Dr. Sarah Hallberg .

Key Points: 
  • Boca Raton, FL, Jan. 30, 2024 (GLOBE NEWSWIRE) -- On Saturday, February 24, at 9:00 AM EST , the Cardiometabolic Health Congress (CMHC)  will host a 4.5-hour live, complimentary legacy course in honor of the late Dr. Sarah Hallberg .
  • Dr. Hallberg passed in March of 2022 after a 5-year battle with stage IV lung cancer.
  • Our high-carb and low-fat diets coupled with processed sugars have put insulin on a roller coaster of sorts.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY® (bexagliflozin) with TheracosBio Partnership

Retrieved on: 
Thursday, February 1, 2024
Partnership, Exercise, Patient, SGLT2, Urination, Urinary tract infection, FDA, Diet, Diabetes, Pharmacy, IPC, SUN, Female, Type 2 diabetes, Insurance, Blood pressure, Pharmacist, Pharmaceutical industry

SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.

Key Points: 
  • SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.
  • IPC, renowned for its commitment to supporting independent pharmacies, is set to be the first pharmaceutical wholesaler in the United States to carry and distribute BRENZAVVY.
  • BRENZAVVY, an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, presents a groundbreaking approach to diabetes care.
  • IPC members and customers will benefit from this exclusive arrangement, reinforcing IPC's commitment to expanding the range of cost-effective, clinically meaningful products available to independent pharmacies.

JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease

Retrieved on: 
Monday, January 22, 2024
Diabetes, Patient, Research, Diabetic nephropathy, Kidney, Kidney failure, Person, T1D, CIHR, SGLT2, Team, University, Kidney disease, Joslin Diabetes Center, Risk, KFOC, Type 2 diabetes, Safety, Public, University of Toronto, SGLT, JDRF, Clinical trial, University Health Network, Pharmaceutical industry

Kidney disease remains a life-threatening complication for those living with diabetes.

Key Points: 
  • Kidney disease remains a life-threatening complication for those living with diabetes.
  • Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease.
  • SUGARNSALT is one of the largest T1D focused kidney disease studies in the world, and it is the only phase 3 clinical trial targeting major kidney disease outcomes.
  • "The Kidney Foundation of Canada is proud to be one of the founding partners on this significant investment to support innovative strategies to treat diabetic kidney disease.

Diabetes Canada awards over $6 million in funding to new research projects

Retrieved on: 
Monday, January 22, 2024
Diabetes, Health, B cell, Research, Diabetes Canada, Daisy Syron Russell, Risk, Leg, Type 2 diabetes, Nix, Caregiver, Insulin resistance, Prediabetes, Pharmaceutical industry

Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.

Key Points: 
  • Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.
  • “To achieve our vision of a world free of the effects of diabetes, Diabetes Canada knows that it needs to harness the transformative and combined power of technological, medical, and scientific research,” says Laura Syron, President and CEO of Diabetes Canada.
  • The winning research projects for this year’s Diabetes Canada’s End Diabetes Awards were rigorously evaluated by scientists with expertise in diabetes research, with input from people with lived experience, and Diabetes Canada’s National Research Council.
  • For almost 50 years, Diabetes Canada has proudly supported outstanding diabetes research in Canada, administering more than $160 million in research grants, awards and partnerships to scientists and clinicians who have dedicated their careers to the fight against diabetes.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, January 23, 2024
Research, Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Health Technology, Hardware, General Health, Health, Science, RF, Know Labs, Type 2 diabetes, International Fair, ATTD, Mayo Clinic, Clinical professor, Conference, Emerging technologies, Treatment, Prediabetes, Abstract, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.
  • These results will be presented by Dr. Virend K. Somers of the Mayo Clinic, who serves as an author and co-investigator on Know Labs’ current clinical research protocol.
  • The protocol assesses the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference.
  • During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Diabetes, Patient, Therapy, Quality-adjusted life year, SOC, Society, Digital, Type 2 diabetes, American Diabetes Association, Better, Cognitive behavioral therapy, Advances in Therapy, ICER, A1C, QALY, Life imprisonment, Prevalence, Pharmaceutical industry

The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.

Key Points: 
  • The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.
  • This suggests that the use of AspyreRx can empower patients to better manage their diabetes with the potential for lifelong advantages.
  • This latest study modeled the cost-effectiveness of AspyreRx plus SoC versus SoC alone in T2D over a lifetime horizon.
  • "The publication of this data, demonstrating that adding AspyreRx to standard of care has the potential to be more effective and less costly than standard of care alone, exemplifies our vision to make societies healthier and meaningfully reduce healthcare costs.”

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.